Knowledge Gaps in the Treatment of Carcinoid Syndrome

Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symptoms of carcinoid syndrome can negatively impact patients' quality of life and functioning. Baseline data collected from a continuing nursing education (CNE)-approved Oncology Nursing Strategy Session titled Optimizing Management of Carcinoid Syndrom...
Continue reading

JMJD6 Identified as a Neuroblastoma Tumorigenic Factor

Researchers have identified the JMJD6 gene as a critical factor for neuroblastoma tumorigenesis, indicating potential for a new targeted drug therapy treatment strategy. The most prevalent solid tumor in early childhood cancers, neuroblastoma comprises 15% of total childhood cancer deaths. Neuroblastoma is distinctive from adult cancers in that it is characterized by frequent chromosome copy number variations, and its most prominent features are gene deletion, amplification, or gain. While chrom...
Continue reading

Predicting Relapse in Pancreatic Neuroendocrine Tumors

Researchers have found a new way to classify non-functional pancreatic neuroendocrine tumors (PNETs) in order to predict which patients will experience relapse. Most PNETs are non-functional, meaning that they do not release excess hormones into the bloodstream. In current practice, patients whose non-functional PNETs are larger than 2 cm are considered at the highest risk of metastatic recurrence following surgery. "As clinical behaviors [of non-functional PNETs] vary widely and distant metasta...
Continue reading

Review of Adrenal Tumors Reveals Treatment Insight

When researchers reviewed follow-up data from a variety of studies on adults with adrenal tumors in order to understand tumor growth, malignant change, variations in hormone function, and occurrence of comorbid cardiometabolic conditions, they realized valuable insights that can aid in treatment of patients with adrenal tumors. Typically, adrenal tumors are benign, but they can develop into cancerous malignancies. Both benign and malignant adrenal tumors can secrete certain hormones, most common...
Continue reading

Antibody-Drug Conjugate Is Powerful Against Neuroblastoma

Researchers at the Cancer Center of Children's Hospital of Philadelphia (CHOP) have developed an antibody-drug conjugate (ADC) that is powerfully effective against mouse models of neuroblastoma expressing wild-type and mutant anaplastic lymphoma kinase (ALK). Neuroblastoma, a cancer of the peripheral nervous system typically found in children younger than 5, is the third most common pediatric cancer and the most common cancer in infants. It accounts for over 10% of all childhood cancer-related d...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.